The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

I've had a genital itch for years. I take prescription drugs which have itchiness listed as a side effect, but I can't ...

Skin conditions are more common than you might think, with perioral dermatitis being one of the most prevalent. You've likely ...

VTAMA cream ... contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu). You are encouraged to ...

2002). It is available in both prescription and over-the-counter preparations. It fights infections of the skin, ears, and eyes. It is manufactured as creams, ointments, lotions, powders ...

Update on FDA Review of VTAMA® (tapinarof) Cream ... Atopic dermatitis (AD), commonly referred to as eczema, is one of the most common inflammatory skin diseases, affects over 26 million people ...

Atopic dermatitis (AD), commonly referred to as eczema, is one of the most common inflammatory skin diseases, affects over 26 million people in the U.S. alone and up to 10% of adults worldwide.

in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or ...